Wednesday, 15 August 2012

Transvasin Heat Rub Cream





1. Name Of The Medicinal Product



Transvasin Heat Rub Cream



Boots Pain Relief Heat Rub


2. Qualitative And Quantitative Composition










Hexyl Nicotinate




2% w/w




Ethyl Nicotinate




2% w/w




Tetrahydrofurfuryl Salicylate




14% w/w



3. Pharmaceutical Form



Cream



4. Clinical Particulars



4.1 Therapeutic Indications



For the relief of rheumatic and muscular pain and the symptoms of sprains and strains.



4.2 Posology And Method Of Administration



Route of administration: Cutaneous



Directions for use



Massage gently into the affected area until the cream is entirely absorbed. Apply at least twice daily until the symptoms abate.



Adults, Children and the Elderly



Quantities are not critical and are not specified on the data sheet. The amount used should be consistent with the directions for use, and will vary with the size of the treated area.



4.3 Contraindications



Sensitivity to the product or any of its ingredients.



4.4 Special Warnings And Precautions For Use



Transvasin/Boots Pain Relief Heat Cream should not be applied to broken or sensitive skin, for example around the eyes or scrotal skin. Avoid use on mucous membranes.



For external use only.



Transvasin/Boots Pain Relief Heat Cream is a rubefacient and within a few minutes of application a sensation of warmth is felt, followed by a reddening of the skin. This erythema does not indicate intolerance.



Discontinue use if rash develops.



Hands should be washed immediately after use.



Not for use with occlusive dressings.



Patients are advised against excessive exposure to sunlight of treated areas in order to avoid the possibility of photosensitivity.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



None known.



4.6 Pregnancy And Lactation



Although there have been no reports of adverse effects, as with all medicines, care should be taken when administering to pregnant or lactating women.



4.7 Effects On Ability To Drive And Use Machines



None known.



4.8 Undesirable Effects



Reported effects have taken the form of localised sensitisation reactions and have invariably subsided following withdrawal of the medication.



4.9 Overdose



As this is a topical application, with small amounts of actives, adverse systemic effects are unlikely, even after oral ingestion.



Treatment:



No special measures are necessary.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Hexyl Nicotinate and Ethyl Nicotinate are rubefacients. Tetrahydrofurfuryl Salicylate is used for musculoskeletal, joint, peri-articular and soft tissue disorders.



5.2 Pharmacokinetic Properties



None stated.



5.3 Preclinical Safety Data



There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Purified Water Ph Eur



Methylhydroxybenzoate Ph Eur



Cetostearyl Alcohol BP



Stearic Acid 1973 BPC



Polysorbate 20 Ph Eur



Sorbitan Monostearate BP



Perfume



6.2 Incompatibilities



None known



6.3 Shelf Life



36 months.



6.4 Special Precautions For Storage



Do not store above 25°C.



6.5 Nature And Contents Of Container



Collapsible aluminium tubes with membrane, containing 3, 3.5, 5, 7.5, 10, 30, 40, 45, 80 or 120g of product with a polyamide-imide lacquer internal coating and polypropylene piercer cap packed in a cardboard outer.



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



7. Marketing Authorisation Holder



Thornton & Ross Ltd



Linthwaite



Huddersfield



West Yorkshire



HD7 5QH



United Kingdom



8. Marketing Authorisation Number(S)



PL 00240/0062



9. Date Of First Authorisation/Renewal Of The Authorisation



12th April 2004



10. Date Of Revision Of The Text



21.01.2008



11 DOSIMETRY (IF APPLICABLE)


Not Applicable



12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)


Not Applicable




No comments:

Post a Comment